EACSGE
27.1.2020 18:26:12 CET | Business Wire | Press release
From February 13th to 14th , the Royal Hotel Carlton in Bologna will be venue of the first edition of the international congress organized by the EACSGE (Esophageal Adenocarcinoma Study Group Europe ), dedicated to basic and clinical research, diagnosis and therapy of gastroesophageal junction adenocarcinoma and Barrett's esophagus (a pathology secondary to gastroesophageal reflux disease, which can lead to esophageal adenocarcinoma).
The initiative is promoted by the EACSGE and coordinated by Sandro Mattioli , Professor at Alma Mater Studiorum - University of Bologna, Director of Thoracic Surgery and the Esophageal Diseases Center at Maria Cecilia Hospital (GVM Care & Research) in Cotignola (Ravenna, Italy) and Prof. Sheila K. Krishnadath of the University Medical Center in Amsterdam (Netherlands).
"For the first time, in the scientific world, basic researchers and clinical specialists in Medical Genetics, Anatomic Pathology, Gastroenterology, Surgery and Oncology will discuss and transform the results obtained in basic research into clinical applications, – Prof. Mattioli explains – in order to make advances in the treatment of esophageal adenocarcinoma , which is now the sixth most frequent cancer in the Western world".
The EACSGE boasts multidisciplinary teams from the Universities of Genoa, Helsinki and Verona, the Vita-Salute University and the European Institute of Oncology in Milan, and the Oncology Institute Research Hospital in Meldola (FC).
The main objectives of the meeting include taking stock of the current state of knowledge on the biology of the disease, determining the predictors of field cancerization in Barrett's esophagus, in order to implement targeted surveillance protocols and evaluating the efficacy of vaccines that show promise in being able to halt the field cancerization process.
The discussion among experts may provide knowledge that can be used to modulate surgical and pharmacological therapies at every stage of the disease. Finally, during the conference, meetings will be held among members of the EACSGE and the event’s Faculty, aimed at expanding the study groups and preparing new research protocols.
There is also space devoted to the future of research: young researchers will have the opportunity to deliver a short presentation on the scientific progress of their studies; the most accurate report will also receive an accolade from the Scientific Committee and the organizers.
The complete event schedule is available at this link: https://www.iec-srl.it/index.php/it/eventi-2020/201-traslational-reserach-for-tha-management-of-barrett-s-esophagus-and-esophageal-adenocarcinoma
View source version on businesswire.com: https://www.businesswire.com/news/home/20200127005551/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chiesi Advances Its Carbon Minimal Inhaler Journey as European Submissions for Its Single Inhaler Triple Therapy (SITT) and ICS/LABA Combination Next-Generation Propellant pMDIs Are Validated3.9.2026 11:00:00 CEST | Press release
Key Highlights Regulatory submissions for next-generation propellant pMDIs (pressurized metered-dose inhalers) across Chiesi’s Single Inhaler Triple Therapy (SITT; or ICS/LABA/LAMA) and fixed double ICS/LABA combination (inhaled corticosteroid with a long-acting bronchodilator) range have been validated by Regulatory Agencies in Europe. Transition to HFA‑152a, a next‑generation propellant classified as non‑PFAS* and with low global warming potential (GWP),aimsto reduce the carbon footprint of Chiesi’s pMDIs by up to 90% compared to current ones.1-3 Designed for a seamless transition for patients and HCPs, maintaining established efficacy, safety and usability and supporting continuity of care.4-8 The validation supports Chiesi’s ambition to reach Net Zero† across its full value chain by 20359, following MHRA approval of Chiesi’s beclometasone pMDIs formulated with HFA-152a. Chiesi Group, an international research-focused biopharmaceutical company and certified B Corp, today announces a
Belkin præsenterer nye løsninger til at strømforsyne, lokalisere og personalisere hverdagens teknologi3.9.2026 10:00:00 CEST | Pressemeddelelse
Belkin International kan findes på IFA-messen i udstillingshal 3.2, stand nr. 117 Belkin, der i mere end 40 år har været globalt førende inden for forbrugerelektronik, annoncerede i dag en ny kollektion af tilsluttet tilbehør, enhedsbeskyttelse og livsstilsløsninger, der er designet til at hjælpe forbrugerne med at holde styr på og personalisere de enheder, de er afhængige af. Den nye portefølje omfatter SureFind-kollektionen, BoostCharge Slim Magnetic Ring Stand, UltraCharge Smart Display-powerbanks og nye farvevarianter af Belkins populære BoostCharge Compact USB-C-oplader 30 W. De nyligt annoncerede produkter bliver præsenteret på IFA 2026, hvor Belkin udstiller på IFA-messen i hal 3.2, stand nr. 117. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20260903932800/da/ Product lineup showcasing Belkin's newest mobile power accessories De nye produkter bygger på idéen om, at teknologi skal passe problemfrit ind i en moderne l
Quectel Expands RG660Qx 5G Module Capabilities for Future Railway Mobile Communication System Evaluation and Railway Applications3.9.2026 10:00:00 CEST | Press release
High-performance Sub-6GHz 5G module platform with support for FRMCS-related frequency bands enables early evaluation through a dedicated development environment. Quectel Wireless Solutions, a global IoT solutions provider, today announced an LGA version of its RG660Qx 5G module series, a high performance, Sub-6GHz 5G module platform that includes support for the Future Railway Mobile Communication System (FRMCS). Used with a dedicated evaluation environment comprising an adaptor board and EVB Kit, the RG660Qx enables equipment manufacturers and railway technology developers to conduct early Future Railway Mobile Communication System (FRMCS) evaluation and testing, supporting development ahead of the transition from GSM-R. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903961434/en/ Quectel expands RG660Qx 5G module capabilities for Future Railway Mobile Communication System evaluation and railway applications The Future R
Belkin introducerer fremtidens bærbare strømforsyning med nye UltraCharge Pro Power Banks med halvfaste celler3.9.2026 10:00:00 CEST | Pressemeddelelse
Den næste generation af bærbar strømforsyning præsenteres for første gang på IFA 2026 og fremviser avanceret BoostSolid Cell-teknologi og ultraslanke design Belkin, der i mere end 40 år har været globalt førende inden for forbrugerelektronik, annoncerede i dag nye bærbare opladningsløsninger baseret på halvfast celleteknologi. Den nye UltraCharge Pro med BoostSolid Cell-serie er blandt Belkins første produkter med halvfast celleteknologi, et batteri af næste generation, der leverer forbedret holdbarhed, slankt design og længere batteritid – alt sammen uden at gå på kompromis med ydeevnen. De nyligt annoncerede produkter bliver præsenteret på IFA 2026, hvor Belkin udstiller på IFA-messen i hal 3.2, stand nr. 117. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20260903417354/da/ Product image showcasing the first two Belkin power banks launched with BoostSolid technology Batteriteknologi af næste generation til længerevarende
I’m green™ bio-based Helps Deterra® Win Multiple Industry Awards for Pharmaceutical Packaging3.9.2026 10:00:00 CEST | Press release
The Deterra® Drug Disposal Pouch, which is made with 50% or more I'm green™ bio-based polymer, has gained Accredo Packaging a number of leading packing industry awards. Developed by Verde, the patented drug disposal technology is designed to deactivate unused medications, preventing drug diversion and mitigating the risk of pharmaceuticals leaching into groundwater and waterways. The partial use of I’m green™ bio-based polymer derived from renewable sugarcane, reduces the carbon footprint of the packaging material compared to equivalent fossil-based polyethylene, all whilst maintaining the technical performance required for pharmaceutical disposal applications. Material Innovation and Application The Deterra® pouch required a material that could meet strict technical specifications without relying entirely on traditional, fossil-based plastics. By utilizing I’m green™ bio‑based polyethylene, the packaging has a reduced carbon footprint whilst maintaining the performance of conventional
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
